Abstract
Programmed cell death (pcd) is a form of cell death in which the cell plays an active role in its own demise. Pcd plays a critical role in the development of the nervous system, as well as in its response to insult. Both anti-pcd and pro-pcd modulators play prominent roles in development and disease, including neurodegeneration, cancer, and ischemic vascular disease, among others. Over 100,000 published studies on one form of programmed cell death — apoptosis — have appeared, but recent studies from multiple laboratories suggest the existence of non-apoptotic forms of programmed cell death, such as autophagic programmed cell death. In addition, there appear to be programmatic cell deaths that do not fit the criteria for either apoptosis or autophagic cell death, arguing that additional programs may also be available to cells. Constructing a mechanistic taxonomy of all forms of pcd — based on inhibitors, activators, and identified biochemical pathways involved in each form of pcd — should offer new insight into cell deaths associated with various disease states, and ultimately offer new therapeutic approaches.
Keywords: Programmed cell death, autophagy, caspase, apoptosis, paraptosis, dependence receptors, neurodegeneration, Alzheimer's disease
Current Molecular Medicine
Title: Programmed Cell Death Mechanisms in Neurological Disease
Volume: 8 Issue: 3
Author(s): Dale E. Bredesen
Affiliation:
Keywords: Programmed cell death, autophagy, caspase, apoptosis, paraptosis, dependence receptors, neurodegeneration, Alzheimer's disease
Abstract: Programmed cell death (pcd) is a form of cell death in which the cell plays an active role in its own demise. Pcd plays a critical role in the development of the nervous system, as well as in its response to insult. Both anti-pcd and pro-pcd modulators play prominent roles in development and disease, including neurodegeneration, cancer, and ischemic vascular disease, among others. Over 100,000 published studies on one form of programmed cell death — apoptosis — have appeared, but recent studies from multiple laboratories suggest the existence of non-apoptotic forms of programmed cell death, such as autophagic programmed cell death. In addition, there appear to be programmatic cell deaths that do not fit the criteria for either apoptosis or autophagic cell death, arguing that additional programs may also be available to cells. Constructing a mechanistic taxonomy of all forms of pcd — based on inhibitors, activators, and identified biochemical pathways involved in each form of pcd — should offer new insight into cell deaths associated with various disease states, and ultimately offer new therapeutic approaches.
Export Options
About this article
Cite this article as:
Bredesen E. Dale, Programmed Cell Death Mechanisms in Neurological Disease, Current Molecular Medicine 2008; 8 (3) . https://dx.doi.org/10.2174/156652408784221315
DOI https://dx.doi.org/10.2174/156652408784221315 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine A Cross-entropy-based Method for Essential Protein Identification in Yeast Protein-protein Interaction Network
Current Bioinformatics PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology GSTP1 Polymorphisms and their Association with Glutathione Transferase and Peroxidase Activities in Patients with Motor Neuron Disease
CNS & Neurological Disorders - Drug Targets Sirtuins as Possible Targets in Neurodegenerative Diseases
Current Drug Targets Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member:
Current Alzheimer Research Intracellular and Extracellular Zinc Detection by Organic Fluorescent Receptor
Current Organic Chemistry Patterns of Cognitive Impairment in Neurological Disease
Current Psychiatry Reviews Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Quantitative Ultrasound of Orofacial Muscles in Infants from 6 Months to 5 Years: Collecting Normal Values
Current Medical Imaging Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
Mini-Reviews in Organic Chemistry